CVS Health Reports Strong Q3 Earnings, Signals Insurance Unit Recovery
Takoma Park, Maryland — CVS Health’s financial performance for the third quarter exceeded expectations, showcasing significant growth across its business segments as the company restructures under the leadership of CEO David Joyner. This comes as a promising sign after a challenging period under former CEO Karen Lynch.
On Wednesday, CVS announced that its adjusted earnings per share (EPS) for the third quarter soared to $1.60, far surpassing analyst projections of $1.37. The company also reported revenues of $102.87 billion, outperforming expectations of $98.85 billion—marking a year-over-year increase of 7.8%. However, the company faced a net loss of $3.99 billion, primarily due to a $5.7 billion goodwill impairment charge related to its healthcare delivery segment.
Leadership Changes and Growth Outlook
Joyner noted that the company raised its fiscal 2025 adjusted earnings guidance to a range of $6.55 to $6.65 per share, up from previous predictions of $6.30 to $6.40. “I couldn’t be more happy about the fact that this is three quarters where we’ve had a beat and raise,” Joyner stated during an earnings call, expressing optimism about closing the year strong.
The turnaround appears to align with improvements in the company’s insurance unit, Aetna, which faced high medical costs last year as more individuals resumed delayed procedures post-COVID-19. Joyner emphasized that Aetna’s transformation was evident, with a notably reduced medical benefit ratio of 92.8%, down from 95.2% a year ago. This ratio signifies that the insurer’s premiums outpaced its medical claims, suggesting improved profitability.
Robust Performance Across Segments
All three of CVS’s business units exceeded revenue expectations:
-
Insurance Segment: Generated $35.99 billion in revenue, a 9% increase from the same quarter last year. This boost has been attributed to enhanced performance in its government business, influenced by the Inflation Reduction Act’s impact on Medicare Part D premiums.
-
Pharmacy and Consumer Wellness Division: Achieved sales of $36.21 billion, driven by elevated prescription volumes—partly from CVS’s acquisition of Rite Aid’s prescription business. This segment reported an 11.7% increase year-over-year, despite facing reimbursement pressures.
-
Health Services Segment: Contributed $49.27 billion in revenue, reflecting an 11.6% rise compared to the previous year and marking significant contributions from Caremark, which negotiates drug discounts on behalf of insurers.
Joyner remarked on the solid performance of CVS Pharmacy and expressed confidence in the pharmacy unit’s potential to maintain momentum as it moves into 2026.
Strategic Adjustments
Despite the favorable outcomes, CVS is taking a strategic approach to its healthcare delivery segment. Joyner revealed that the company is slowing down clinic growth and closing underperforming locations, including 16 facilities operated under Oak Street Health. Although these decisions may reflect challenges within the segment, Joyner emphasized a continued commitment to value-based care, stating that Oak Street Health’s performance is on track.
Closing Thoughts
CVS Health’s third-quarter results set a positive tone as the company consolidates its efforts to improve profitability and shareholder value. With substantial growth across its business units and effective management strategies in place, CVS appears well-positioned for continued success heading into 2026.
